PharmaCyte Biotech
PMCB
26 hedge funds and large institutions have $8.68M invested in PharmaCyte Biotech in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 5 closing their positions.
96% more capital invested
Capital invested by funds: $4.42M → $8.68M (+$4.25M)
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
18% more funds holding
Funds holding: 22 → 26 (+4)
10.02% more ownership
Funds ownership: 6.74% → 16.75% (+10%)
26% less call options, than puts
Call options by funds: $226K | Put options by funds: $305K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Shay Capital
New York
|
+$1.78M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.69M |
| 3 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
+$713K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$572K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$533K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$159K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$153K |
| 3 |
NP
NorthRock Partners
Minneapolis,
Minnesota
|
-$118K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$17.7K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$13.1K |
PMCB Hedge Fund Activity: Q4 2021 in Review
26 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q4 2021, worth a combined $8.68M — up 96% from $4.42M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PMCB positions and 5 closed out — a net gain of 4 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Shay Capital, adding an estimated $1.78M. The largest seller was Schonfeld Strategic Advisors, cutting an estimated $159K.
- 26 institutional investors held PharmaCyte Biotech (PMCB) as of Q4 2021, up from 22 in Q3 2021.
- Funds reported $8.68M of PharmaCyte Biotech stock for Q4 2021, up 96% quarter-over-quarter.
- 9 funds opened new PharmaCyte Biotech positions in Q4 2021 and 5 closed out, a net change of +4 holders.
- The largest PharmaCyte Biotech buyer in Q4 2021 was Shay Capital, an estimated $1.78M added.
- The largest PharmaCyte Biotech seller in Q4 2021 was Schonfeld Strategic Advisors, an estimated $159K sold.
Based on aggregated 13F filings for Q4 2021.